Phase IIGLP-1
Compound 62203
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-062203
Risk Class
HIGH
Last Audit
Feb 25, 2109
Research Abstract
GLP-1 candidate engineered for oncology adjuvant initiatives with automated dossier coverage.
Compound 62203 is a glp-1 asset inside glp-1 innovation track initiatives, optimized for oncology adjuvant and inflammation control.
The dossier currently sits in phase ii with a high risk rating, meaning it is restricted to black-box teams with hardened compliance.
Supply records cite CAS AUTO-062203 with updates logged 2109-02-25.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Oncology adjuvantInflammation control
Nomenclature
CX-62203GLP-1 Program 62203
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-062203
- [2] Operations Pulse • GLP-1 innovation track
- [3] Risk Governance Ledger • HIGH clearance for COMPOUND-62203